Soaking bone grafts in a bisphosphonate solution before implantation can prevent their resorption and increase the local bone density in rats and humans. However, recent studies suggest that pre-treatment of allografts with bisphosphonate can prevent bone ingrowth into impaction grafts. We tested the hypothesis that excessive amounts of bisphosphonate would also cause a negative response in less dense grafts. We used a model where nonimpacted metaphyseal bone grafts were randomised into three groups with either no bisphosphonate, alendronate followed by rinsing, and alendronate without subsequent rinsing, and inserted into bone chambers in rats. The specimens were evaluated histologically at one week, and by histomorphometry and radiology at four weeks. At four weeks, both bisphosphonate groups showed an increase in the total bone content, increased newly formed bone, and higher radiodensity than the controls. In spite of being implanted in a chamber with a limited opportunity to diffuse, even an excessive amount of bisphosphonate improved the outcome. We suggest that the negative results seen by others could be due to the combination of densely compacted bone and a bisphosphonate.
Soaking bone grafts in a bisphosphonate solution before implantation can prevent their resorption and increase the local bone density in rats and humans. However, recent studies suggest that pre-treatment of allografts with bisphosphonate can prevent bone ingrowth into impaction grafts. We tested the hypothesis that excessive amounts of bisphosphonate would also cause a negative response in less dense grafts. We used a model where nonimpacted metaphyseal bone grafts were randomised into three groups with either no bisphosphonate, alendronate followed by rinsing, and alendronate without subsequent rinsing, and inserted into bone chambers in rats. The specimens were evaluated histologically at one week, and by histomorphometry and radiology at four weeks. At four weeks, both bisphosphonate groups showed an increase in the total bone content, increased newly formed bone, and higher radiodensity than the controls. In spite of being implanted in a chamber with a limited opportunity to diffuse, even an excessive amount of bisphosphonate improved the outcome. We suggest that the negative results seen by others could be due to the combination of densely compacted bone and a bisphosphonate.
We suggest that bisphosphonates are likely to have a negative influence where resorption is a prerequisite to create space for new bone ingrowth.
Bone grafts are commonly used in orthopaedic surgery, but graft bone is often resorbed during revascularisation. If not matched by new bone formation, this may cause temporary mechanical weakening of an implant. If a graft fails mechanically after the first few months, it is likely to be an effect of resorption. The initial stability of a joint replacement improves the success rate. 1, 2 When bone grafts are used in joint revision it is desirable to achieve new bone formation without temporary mechanical weakening, which might compromise the stability of the graft and the implant. A graft pretreated with a bisphosphonate can be protected from resorption which also enhances its osteoconductive effect leading to more bone ingrowth. 3 Such treatment has increased the density of the graft in a randomised trial on patients undergoing revision of total hip replacement. 4 Bisphosphonates are a class of drugs used to counter the effects of diseases that affect bone turnover. They have a strong affinity for bone mineral, especially in regions undergoing bone resorption or formation. As a consequence, they are selectively taken up and concentrated in bone. Nitrogen-containing bisphosphonates, such as alendronate, inhibit the perioxisomal enzyme farnesyl pyrophosphate synthase. Blocking this enzyme affects the mevalonate pathway, which interferes with prenylation of proteins. This interference impairs osteoclast function and hence reduces bone resorption. 5 Systemic treatment with bisphosphonate will mostly reach the revascularised parts of the bone, but not the non-vascularised graft. By treating bone locally with a bisphosphonate, it can be given protection against resorption, without affecting the entire skeleton. Higher local concentrations of bisphosphonate can be achieved than by systemic treatment and this may be needed in situations where bone resorption is rampant, 6 such as occurs when bone grafts are used.
There is concern that local treatment of grafts with bisphosphonates can cause unwanted effects. Recent studies contradict earlier observations and suggest that treating an allograft with a bisphosphonate could impair fixation of the implant. 7, 8 Depending on the dose, bisphosphonates influence both osteoclasts and osteoblasts. Studies in vitro have found that micromolar concentrations of bisphosphonates induce osteoblast apoptosis and restrict proliferation. 9, 10 However, nanomolar concentrations seem to have a positive effect on osteoblasts and osteocytes. 11, 12 It is therefore important to determine in what way large amounts of locally applied bisphosphonates influence the bone in vivo.
The aim of this study was to see whether an excess dose of alendronate combined with allograft bone would have a negative effect on bone formation. We used an animal model in which previous experiments with lower doses had shown a positive effect. 3 Our hypothesis was that large amounts of alendronate in an isolated volume would lead to less bone formation and ingrowth. Furthermore, we wished to investigate how the surrounding bone would be affected by alendronate originating from the graft. We also tried to establish the amounts of alendronate that were absorbed and released from the grafts under these conditions.
Materials and Methods
Alendronate-treated rat allograft bone was inserted into titanium chambers and implanted in 70 rats. After four weeks, histomorphometry was used to determine the response to the treatment. Animal model. We used the bone conduction chamber as a model for membraneous ossification. 13, 14 This system has previously been used in several studies involving allografts and bisphosphonates. [15] [16] [17] [18] [19] [20] The chamber consists of a titanium screw with a cylindrical interior space. It is made up of two threaded half-cylinders held together by a hexagonal closed screw cap. One end of the implant is screwed into the bone. The interior of the chamber has a diameter of 2 mm and a length of 7.5 mm. There are two openings at the end of the chamber to enable bone access. Thus, the ingrowing tissues enter the cylindrical space from the bone compartment. The chamber extends far out into the subcutaneous region and ingrowth of bone-derived tissue can fill the chamber without competing with other tissue (Fig. 1) . Thus, the ingrowth distance of newly formed tissue from the openings towards the other end of the chamber can be used to estimate tissue regeneration. The geometry of the chamber makes it easy to distinguish areas for histomorphometry.
Graft procurement and treatment. Structurally intact cancellous bone grafts were obtained from female SpragueDawley rats (200 g). A cylindrical rod of bone 2 mm in diameter and 6 mm long was resected in the axial direction from the knee joint with a trephine. The epiphysis and the growth plate were excised. The proximal part of the graft had the most dense cancellous bone and was later turned towards the ingrowth end of the chamber. The grafts were kept sterile and frozen at -70°C.
A 2.0 mg/ml solution of alendronate was prepared by dissolving solid sodium-alendronate trihydrate powder (Calbiochem, Darmstadt, Germany) in saline for one hour under sonication, and then passing it through a sterile 0.2 μm/Millipore filter. Before insertion into the bone conduction chambers the grafts were treated with one of the three following solutions: alendronate 2 mg/ml for ten minutes, then rinsed three times in saline for three minutes each time (regular treatment); alendronate solution for ten minutes, but no rinsing (overdose treatment); saline rinsing for ten minutes (control treatment). The volumes of saline used were 2 ml and of alendronate 10 ml. Thereafter, the grafts were placed in bone chambers which were implanted unilaterally in the cancellous part of the tibia of the recipient rats. Operative procedure. Under aseptic conditions, a longitudinal incision was made over the anteromedial aspect of the proximal tibial metaphysis. After the periosteum had been incised and raised, the medial and posterolateral cortices were pierced with a 1.2 mm diameter needle just anterior to the insertion of the medial collateral ligament. A 3.2 mm diameter drill was then used to enlarge the hole created in the medial cortex. The chamber was then screwed into the hole until the cap rested on the metaphysis. Study design. The chambers were implanted for four weeks for histomorphometry, and for one week for qualitative histology. The shorter time span was used to observe any acute toxic effects. The study was initially designed to include 30 animals, but when it was discovered that there also seemed to be increased bone formation outside some chambers, the protocol was modified and a second experimental series of 40 rats was used and radiographs were taken. In order to increase the power of the study, both groups were pooled and evaluated simultaneously. Thus, first 30 and subsequently 40 additional male Sprague-Dawley rats (350 g) were randomised into the three groups, each of which was managed identically. At four weeks, the three groups of rats were killed and their tibiae harvested. For qualitative measurements, ten animals were killed after one week, with three in the regular, three in the overdose group and four in the control group chosen at random. Institutional guidelines for the care and treatment of experimental animals were followed. The animal experiments were approved by the regional board for the welfare of experimental animals. Radiological evaluation. When removing the chambers of the first experimental series it was noticed that some were much better fixed to the bone than others. This suggested that the bone surrounding the chamber was also affected by the bisphosphonate treatment. Therefore, in the second experiment, before the chambers were removed from the tibia, a radiograph was taken of the bone surrounding the chamber (Fig. 2) within one hour using an MX 20 radiography system (Faxitron X-ray Corporation, Wheeling, Illinois). The bone density outside the chamber screw was graded from the images using a three-step scale both independently by the authors and by an independent blinded observer. Histological evaluation. The grafts were removed from the chambers, decalcified and prepared for histological examination with sections parallel to the long axis of the chamber and stained with haematoxylin and eosin. Three sections in each specimen were studied, each 250 μm apart. After three months, a sample of specimens was recounted to determine the evaluation error. All sections were blinded for identity and evaluated in random order.
Grafts were evaluated after one week based on three parameters, namely the proportion of inflammatory cells, the size of the necrotic areas and the presence of spindleshaped cells, and graded from 0 to 3. The evaluation at four weeks was done by manual point counting of an area of interest from the bottom of the chamber, the ingrowth end, to the frontier of the advancing new bone formation, but only comprising the central third of the specimen so that bone close to the titanium walls was excluded. The total number of points, points covering bone in general and points covering new living bone were counted. We distinguished between graft bone and new bone by evaluating the staining of the bone matrix, which is paler and more uneven in the graft, the presence of osteocytes, and the trabecular shape. On average 305 points were counted per specimen. A random sample of 12 specimens was reassessed after three months to measure the standard error of measurement, which was 2.8% for new bone and 2.5% for graft bone. The bone ingrowth distance was measured by computer-aided means described elsewhere. Briefly, the area covered by new bone was divided by the width of the sample to yield ingrowth distance.
14 Determination of graft-bound alendronate. A 6 mM solution of sodium-alendronate trihydrate (Calbiochem, Darmstadt, Germany) containing 0.25%/w 100 μCi/ml 14 C-labelled alendronate (Moravek Radiochemicals, Brea, California) was prepared. A total of nine cylindrical bone grafts, obtained in the same way as the implanted grafts, were submerged for ten minutes in the 14 C-labelled alendronate solution. The grafts were then rinsed three times in saline for three minutes on each occasion, in an identical manner to the treatment of the regular group. Aliquots were taken after each rinsing step, and mixed with Optiphase Supermix scintillation fluid (Perkin Elmer, Chelton, Connecticut) and counted in a LKB 1217 Racbeta liquid scintillation counter (Wallac, Åbo, Finland). The amount of fluid taken up by the cylinders was estimated by weighing the specimens during the treatment. Statistical methods. Statistical analysis was performed with analysis of variance (ANOVA) and Tukey-Kramer post hoc tests. The main hypothesis was that a high dose of alendronate (overdose) would impairincorporation of bone graft compared with a lower dose (regular). The results are presented as means with the 95% confidence intervals (CI) for the differences between means. The data were analysed using JMP 7.0 statistical software (SAS Institute Inc., Cary, North Carolina). Statistical significance was set at p < 0.05. Results There were 13 exclusions, which were all made while all involved persons were blinded, two because of external infection of the chamber, two due to faulty placement of the chambers, three due to errors during preparation for histology, and six because parts of the growth plate had been inserted into the chamber. Of the 13 exclusions, two belonged to the control, five to the regular and six to the overdose groups. Qualitative histology. Soft tissue had invaded the entire graft after seven days, with numerous inflammatory cells present and some necrosis. However, it was not possible to see an immediate toxic response to the excessive alendronate content (Table I ). There was no new bone present and no sign of bone resorption inside the grafts at this early stage.
After four weeks the alendronate-treated grafts were mostly unresorbed, with new bone lining the graft bone. There were no obvious differences between the two alendronate groups. The controls were easily distinguishable, as the graft had been resorbed, enabling haematogenous marrow to form inside the resorbed space. In all treatment groups a bone ingrowth frontier had formed. About a third of the graft remained beyond this frontier. Histomorphometry. After four weeks, both alendronate groups showed more newly formed bone and more total bone content than the controls (Table II) . However, there were no significant differences between groups as regards the content of bone graft and bone ingrowth distance. The regular and overdose groups had a larger content of new bone than the controls, but there was no significant difference between them (Table III) . The 95% CI for the difference between the means of the two alendronate groups for new bone formation excludes a reduction by more than 19% found in the alendronate overdose group.
The mean total bone content was larger in both the regular and the overdose groups, compared with the controls. There was no significant difference between the regular and the overdose groups, and the 95% CI for the difference between the means of the two alendronate groups excludes a reduction by more than 8% resulting from overdosing. Similarly, the 95% CI excluded that the ingrowth distance was reduced by more than 24% by the alendronate overdose. Radiological evaluation. In all, 27 samples were evaluated. There were three exclusions, which were made while all involved persons were blinded, two due to external infection and one because the tibia fractured when harvested. Controls had a lower bone density score, in the bone surrounding the chamber, compared with the other specimens (Table IV) . However, there was no significant difference Table I . Histological grading of the seven-day grafts. Each specimen is described by one number. Scale from 0 (none), 1 (present), 2 (few), to 3 (abundant) between the regular and the overdose groups. An independent person, who was asked to select the ten specimens with the least bone surrounding the screws, identified nine of the ten controls correctly. Alendronate uptake and release. The graft absorbed a mean of 10.6 μL (SD 1.4) of alendronate solution per graft, representing a total amount of 21 μg alendronate. This would yield a 3.7 mM concentration inside the chamber in the overdose group. After the rinsing procedures, a mean of 141 ng (SD 29) of alendronate remained adsorbed to the bone of the graft and was thus implanted in the regular group.
Discussion
Contrary to our hypothesis, a large initial dose of alendronate did not cause any adverse effects. There were two sources of alendronate in the chamber. First, there was the amount which had been adsorbed to the bone surface, around 141 ng per graft. The second source was the concentrated alendronate solution contained in the graft. This was the largest source, with 150 times more alendronate contained in this way. It is reasonable to believe that most of this alendronate solution was eliminated via diffusion through the ingrowth openings of the chamber. However, there would still be parts of the graft where high concentrations were present for longer periods. We also found an increase in bone density around the chambers, surrounding the ingrowth holes in both alendronate groups. This suggests that alendronate from the grafts found its way through the ingrowth openings and into the surrounding bone. This is surprising, as the regular group had been thoroughly rinsed. Hence, it is reasonable to assume that alendronate was slowly released from the graft by desorption 5, 21 or by osteoclastic resorption, 5, 22 and transported to the surrounding bone, where it again adhered.
Both alendronate groups showed a beneficial effect of bisphosphonate treatment, with increased total bone content and increased formation of new bone. The 95% CI excluded a detrimental effect of the overdose of a relevant magnitude. The lack of a difference in retained allograft bone was unexpected, as we have previously seen less bone in control specimens than in alendronate-treated ones. 3 We believe that this is due to the four-week period of study in this experiment instead of the six weeks used in earlier work. 3 Shortening the time span may have meant that there was not enough time to fully resorb all graft bone behind the bone ingrowth frontier.
We did not observe the negative effects of bisphosphonate treatment that others have reported. 7, 8 This could be due to the difference in models, which warrants caution when making direct comparisons. We chose to use bone ingrowth chambers in rats, whereas the negative results were found in models with an implant inserted into canine bone and graft applied around it. Apart from the species, the local conditions may be different, especially as the material in the chamber is not exposed to mechanical loading. However, some comparisons can be made regarding bone volumes and density of inserted grafts. In our controls, the volume fraction of new bone and total bone were of the same magnitude as in the controls in the study by Jakobsen et al. 7 In alendronate-treated specimens, we even saw increased formation of new bone compared with controls. The reason why we saw no deleterious effect, whereas Jakobsen et al 7 found impaired fixation, could be that we did not impact the allografts in the chambers. It has previously been shown that excessive impaction of a graft inhibits new bone formation and ingrowth. 23 It has also been shown that this cannot be overcome by applying growth factors or bisphosphonates. 18 If the density of the graft is excessive, some has to be resorbed to make space for new bone.
Studies have described a positive effect of topical administration of alendronate with bone impaction in dogs in situ, [24] [25] [26] but have used a model similar to the studies 7, 8 reporting a negative effect. The main difference between the positive and the negative canine studies appears to be the use of compacted fine bone allograft granules as opposed to impaction of host bone in situ. Hence, we find it unlikely that the difference in results between dog and rat models could be fully attributed to a difference in the species and believe that the main difference appears to be the methods of administration. The limitations of this and earlier studies warrant further investigation of the benefit of pre-treating allograft with bisphosphonates during joint replacement. In spite of our results, we still believe it wise to rinse away excess bisphosphonate before implanting allografts in humans. Even small amounts of bisphosphonates have an effect on allograft resorption. 27 It has been shown that rinsing grafts does not cause any negative effects but that, on the contrary, bone formation and growth increases. 28 In our model, even large amounts of alendronate in a confined space had the desired effect of protection of the graft and increased bone ingrowth. There were also signs of redistribution of the bisphosphonate, leading to increased amounts of bone in the vicinity of the implanted graft. We were unable to reproduce the negative effects reported by others, and speculate that these have occurred when the allograft was first compressed or impacted and then treated with a bisphosphonate. Still, we believe it wise to wash away non-bound bisphosphonate before implantation in order to minimise the probability that excess doses are delivered to the patient. Although we believe that topical treatment of an allograft with bisphosphonates appears to be a good way to reduce its resorption, further clinical studies should complement the investigation which we have already performed 4 to fully test the benefit of the procedure.
